FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973204839> ?p ?o ?g. }

• W1973204839 endingPage "947" @default.
• W1973204839 startingPage "942" @default.
• W1973204839 abstract ": To determine the toxicity and efficacy of concurrent 5-fluorouracil (5-FU), cisplatin, and paclitaxel (Taxol) and hyperfractionated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. : Twenty-seven patients were entered into this Phase II trial. Eligible patients had Stage III or IV head-and-neck squamous cell carcinoma arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, or larynx. The plan of treatment consisted of hyperfractionated radiotherapy (74.4 Gy at twice daily fractions of 1.2 Gy). Chemotherapy was given on Weeks 1, 5, and 8 as follows: 5-FU at 750 mg/m2 as a constant infusion for 24 h for 3 days; cisplatin at 50 mg/m2 in 250–500 mL D5 0.5 NS or NS infusion during 2–4 h, and paclitaxel at 70 mg/m2 infused in 500 mL NS during 3 h. : The overall survival rate of the entire group was 81.5%, 66.7%, and 63% at 1, 2, and 3 years, respectively. The median follow-up was 40.2 months (range 30–62). Of the 27 patients, 19 (70%) had a complete response and an overall survival rate of 100% at 1 year and 94% at 2 and 3 years. The disease-free survival rate of the latter group was 95% at 1 year and 84% at 2 and 3 years. Of the 27 patients, 18 (67%) maintained the complete response until the last follow-up visit or death. Percutaneous endoscopic gastrostomy dependency occurred for a median of 7.1 months. Grade 3 and 4 mucositis occurred in 20 and 3 patients, respectively. Six patients were hospitalized for leukopenic fever. Late toxicities included L’Hermitte syndrome (n = 3), osteoradionecrosis (n =1), hypothyroidism (n = 4), paresthesias (n = 1), aspiration pneumonia (n = 3), and esophageal strictures (8 patients underwent dilation). : Combining hyperfractionated radiotherapy concurrently with 5-FU, cisplatin, and paclitaxel results in acceptable efficacy and toxicity. However, although a locoregional control benefit is suggested by the preliminary results of this trial, it needs to be confirmed in a prospective randomized trial." @default.
• W1973204839 created "2016-06-24" @default.
• W1973204839 creator A5005223148 @default.
• W1973204839 creator A5010330778 @default.
• W1973204839 creator A5010371831 @default.
• W1973204839 creator A5011893289 @default.
• W1973204839 creator A5040175506 @default.
• W1973204839 creator A5046696100 @default.
• W1973204839 creator A5089302664 @default.
• W1973204839 date "2002-07-01" @default.
• W1973204839 modified "2023-10-16" @default.
• W1973204839 title "Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol" @default.
• W1973204839 cites W1723772693 @default.
• W1973204839 cites W1759456481 @default.
• W1973204839 cites W1925051373 @default.
• W1973204839 cites W1936206127 @default.
• W1973204839 cites W1986884101 @default.
• W1973204839 cites W1999163407 @default.
• W1973204839 cites W2007531271 @default.
• W1973204839 cites W2009210032 @default.
• W1973204839 cites W2022395184 @default.
• W1973204839 cites W2050231648 @default.
• W1973204839 cites W2054830113 @default.
• W1973204839 cites W2071138848 @default.
• W1973204839 cites W2086025907 @default.
• W1973204839 cites W2104854477 @default.
• W1973204839 cites W2139554459 @default.
• W1973204839 cites W2146148650 @default.
• W1973204839 cites W2152609192 @default.
• W1973204839 cites W2155019837 @default.
• W1973204839 cites W2171463571 @default.
• W1973204839 cites W2304036117 @default.
• W1973204839 cites W2331395194 @default.
• W1973204839 cites W2332065761 @default.
• W1973204839 cites W2562414697 @default.
• W1973204839 cites W4293241248 @default.
• W1973204839 cites W4317676035 @default.
• W1973204839 doi "https://doi.org/10.1016/s0360-3016(02)02816-x" @default.
• W1973204839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12095561" @default.
• W1973204839 hasPublicationYear "2002" @default.
• W1973204839 type Work @default.
• W1973204839 sameAs 1973204839 @default.
• W1973204839 citedByCount "22" @default.
• W1973204839 countsByYear W19732048392013 @default.
• W1973204839 countsByYear W19732048392014 @default.
• W1973204839 countsByYear W19732048392015 @default.
• W1973204839 countsByYear W19732048392016 @default.
• W1973204839 crossrefType "journal-article" @default.
• W1973204839 hasAuthorship W1973204839A5005223148 @default.
• W1973204839 hasAuthorship W1973204839A5010330778 @default.
• W1973204839 hasAuthorship W1973204839A5010371831 @default.
• W1973204839 hasAuthorship W1973204839A5011893289 @default.
• W1973204839 hasAuthorship W1973204839A5040175506 @default.
• W1973204839 hasAuthorship W1973204839A5046696100 @default.
• W1973204839 hasAuthorship W1973204839A5089302664 @default.
• W1973204839 hasConcept C126322002 @default.
• W1973204839 hasConcept C141071460 @default.
• W1973204839 hasConcept C143998085 @default.
• W1973204839 hasConcept C146357865 @default.
• W1973204839 hasConcept C151730666 @default.
• W1973204839 hasConcept C2776283816 @default.
• W1973204839 hasConcept C2776694085 @default.
• W1973204839 hasConcept C2777292972 @default.
• W1973204839 hasConcept C2777546739 @default.
• W1973204839 hasConcept C2778239845 @default.
• W1973204839 hasConcept C2778496288 @default.
• W1973204839 hasConcept C2780456651 @default.
• W1973204839 hasConcept C509974204 @default.
• W1973204839 hasConcept C71924100 @default.
• W1973204839 hasConcept C86803240 @default.
• W1973204839 hasConceptScore W1973204839C126322002 @default.
• W1973204839 hasConceptScore W1973204839C141071460 @default.
• W1973204839 hasConceptScore W1973204839C143998085 @default.
• W1973204839 hasConceptScore W1973204839C146357865 @default.
• W1973204839 hasConceptScore W1973204839C151730666 @default.
• W1973204839 hasConceptScore W1973204839C2776283816 @default.
• W1973204839 hasConceptScore W1973204839C2776694085 @default.
• W1973204839 hasConceptScore W1973204839C2777292972 @default.
• W1973204839 hasConceptScore W1973204839C2777546739 @default.
• W1973204839 hasConceptScore W1973204839C2778239845 @default.
• W1973204839 hasConceptScore W1973204839C2778496288 @default.
• W1973204839 hasConceptScore W1973204839C2780456651 @default.
• W1973204839 hasConceptScore W1973204839C509974204 @default.
• W1973204839 hasConceptScore W1973204839C71924100 @default.
• W1973204839 hasConceptScore W1973204839C86803240 @default.
• W1973204839 hasIssue "4" @default.
• W1973204839 hasLocation W19732048391 @default.
• W1973204839 hasLocation W19732048392 @default.
• W1973204839 hasOpenAccess W1973204839 @default.
• W1973204839 hasPrimaryLocation W19732048391 @default.
• W1973204839 hasRelatedWork W2050519138 @default.
• W1973204839 hasRelatedWork W2085978374 @default.
• W1973204839 hasRelatedWork W2100029565 @default.
• W1973204839 hasRelatedWork W2363409655 @default.
• W1973204839 hasRelatedWork W2376593068 @default.
• W1973204839 hasRelatedWork W2381750987 @default.
• W1973204839 hasRelatedWork W3022348405 @default.
• W1973204839 hasRelatedWork W3030792222 @default.

• next